Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383731 | 0.93 | TSHR (0.32) | TSHR | |
| SCHEMBL4818972 | 0.91 | TSHR (0.31) | TSHR | |
| SCHEMBL19325120 | 0.90 | TSHR (0.31) | TSHR | |
| SCHEMBL14286687 | 0.90 | TSHR (0.31) | TSHR | |
| SCHEMBL20332237 | 0.90 | TSHR (0.31) | TSHR | |
| SCHEMBL12733567 | 0.90 | TSHR (0.42) | TSHR | |
| SCHEMBL566248 | 0.89 | TSHR (0.31) | TSHR | |
| SCHEMBL15935503 | 0.88 | TSHR (0.41) | TSHR | |
| SCHEMBL5308716 | 0.87 | TSHR (0.39) | TSHR | |
| SCHEMBL13169264 | 0.87 | TSHR (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678447-B | Modified nucleic acid monomer compounds and oligonucleotide analogues | 卫材R&D管理有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-3999639-A1 | STABILIZED CRISPR COMPLEXES | Synthego Corporation (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| US-20200181607-A1 | TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-06-11 | — | — | US | disclosed |
| WO-2020109470-A1 | TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-06-04 | — | — | WO | disclosed |
| US-20190330630-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-10-31 | — | — | US | disclosed |
| US-10246709-B2 | Targeting ligands for therapeutic compounds | Arrowhead Pharmaceuticals, Inc. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10006024-B2 | RNA interference agent, method for producing same, and use therefor | GIFU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170253875-A1 | Targeting Ligands For Therapeutic Compounds | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-09-07 | — | — | US | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8114979-B2 | Di-alpha amino anthraquinone compositions | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114979-B2 | Di-alpha amino anthraquinone compositions | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110060150-A1 | METHOD OF DETECTING FLUORESCENCE | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110060150-A1 | METHOD OF DETECTING FLUORESCENCE | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2281798-A1 | Anthraquinone quencher dyes, their methods of preparation and use | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7803536-B2 | Methods of detecting fluorescence with anthraquinone quencher dyes | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803536-B2 | Methods of detecting fluorescence with anthraquinone quencher dyes | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2010-05-13 | — | — | US | disclosed |
| US-20080176761-A1 | Intermediates and Methods for Forming Passivated Surfaces on Oxide Layers and Articles Produced Thereby | APPLERA CORPORATION, APPLIED BIOSYSTEMS GROUP (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246709-B2 | Targeting ligands for therapeutic compounds | FABP1, SNRPE, HAVCR2 | TSHR 2664/4885 |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | TSHR 3336/4885 |
| US-20110060150-A1 | METHOD OF DETECTING FLUORESCENCE | ANXA5, ANTXR2, ANXA4 | TSHR 2401/4885 |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | RNASE1, LDLR, HAVCR2 | TSHR 885/4885 |
| US-20170253875-A1 | Targeting Ligands For Therapeutic Compounds | FABP1, SNRPE, HAVCR2 | TSHR 2664/4885 |
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | POLRMT, POLN, RNASE1 | TSHR 2305/4885 |
| US-20080176761-A1 | Intermediates and Methods for Forming Passivated Surfaces on Oxide Layers and Articles Produced Thereby | POLM, SELP, POLH | TSHR 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.